DISTRIBUTION AGREEMENT
Exhibit 10.4
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
THIS DISTRIBUTION AGREEMENT, dated as of October 3, 2006, is by and between TopSpin
Medical (Israel) Ltd., a corporation incorporated under the laws of the state of Israel (the
“Company”) and TOP Medical B.V., an entity incorporated under the laws of The Netherlands (the
“Distributor”).
Recitals
A. The Company is engaged in the development, manufacture, production and sale of
IntraVascular MRI catheter system for the coronary arteries.
B. The Distributor possesses the sales force, facilities and ability to distribute, market and
promote the sale of the Company’s products in the Territory (as such term is defined below).
C. The Company is willing to enter into this Agreement in order to avail itself of such sales
force, facilities and ability to so market and promote Company’s products.
Agreement
Accordingly, and in consideration of the representations, warranties, agreements and
conditions herein contained, the parties hereto agree as follows:
1. Appointment
1.1 Products. The Company’s products that are subject to this Agreement (the
“Products”) will be: (a) the products described in Exhibit A attached hereto; and (b) any
improvements to the Products or additional Company products in the Field (as such term is defined
in Exhibit A), which improvements or additional products may from time to time be included
herein and on the attached Exhibit A by mutual agreement in writing of the parties hereto.
1.2 Exclusivity. Subject to the terms and conditions contained herein, the Company
hereby grants to the Distributor for the term of this Agreement, the exclusive non transferable
right and license to promote, advertise, market, sell and distribute the Products solely in the
geographic area set forth in Exhibit B (the “Territory”) under the Company’s name, logotype
and trademarks. Except with the express written permission of The Company, which may be granted or
denied in the Company’s sole and absolute discretion, the Distributor shall not sell the Products
to third parties located outside of the Territory and, with respect to the Product, shall not
establish any branch or maintain any distribution depot for the Products outside the Territory
(such third parties and areas being exclusively reserved to the Company or the Company’s other
distributors), provided that nothing in this Agreement is intended (and is not to be construed) to
prevent passive sales (being the sale or other disposition of the Products in response to an
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
unsolicited request from a customer) of the Products by the Distributor anywhere within the
European Economic Area. The Company agrees, to the extent permitted by law and except as otherwise
provided herein, not to appoint any other person, entity or organization located in the Territory
as a distributor or reseller of the Products. The Distributor accepts this appointment and agrees
to use its best efforts in a diligent and consistent manner to promote and develop the full sale
potential of the Products in the Territory and agrees to abide by and comply with all written sales
policies and operating regulations of the Company, as modified from time to time by the Company, in
its sole discretion. In addition, Distributor agrees to take such other actions as may be necessary
or desirable to generate sales in the Territory.
1.3 Subdistributors and Agents. The Distributor will not appoint any subdistributors
or agents to promote or distribute the Products without the prior written consent of the Company,
which may be granted or withheld in the Company’s sole and absolute discretion. The rights of any
permitted subdistributor or agent to distribute any Product will not be any greater than the rights
of the Distributor hereunder. If the Distributor enters into any written agreement with any such
subdistributor or agent, it will be subject to the prior written approval of the Company, at the
Company’s sole and absolute discretion. The Distributor will indemnify and hold the Company
harmless from and against any claim, loss, damage or expense (including attorneys’ fees) suffered
or incurred by the Company relating to any claim threatened or initiated by any subdistributor or
agent appointed by the Distributor.
1.4 Competitive Products. During the term of this Agreement the Distributor will not,
without obtaining the prior written consent of the Company, directly or indirectly, alone, or in
any capacity with another firm, whether as an agent, consultant, independent contractor,
distributor, broker or otherwise, manufacture, promote, sell, distribute or offer for sale or
distribution any goods, products or articles (collectively “Act”) that, in the Company’s reasonable
judgment, directly or indirectly, compete with, perform similar functions to or are used for the
same general purposes as the Products or with the Company in the field of Intravascular diagnostic
catheters and related areas, except with the prior written consent of the Company. For a period of
3 months following the termination of this Agreement, for any reason whatsoever, the Distributor
will not Act in such manner that, in the Company’s reasonable judgment, directly competes with,
performs similar functions to or are used for the same general purposes as the Products or with the
Company in the field of Intravascular diagnostic catheters and related areas, except with the prior
written consent of the Company. Any breach of this Section 1.4 will entitle the Company to
terminate the Agreement in accordance with Sections 7.2(c)(ii) hereunder, without derogating from
any other remedy that the Company may be entitled to in accordance with this Agreement and any
applicable law.
2. Orders for Products
2.1 Purchase Orders. The Distributor will, from time to time, submit written purchase
orders to the Company for the Products. Each purchase order will, at a minimum, include: (a)
identification of the Products ordered; (b) quantity, which, with respect to each purchase
order, will not include less than the minimum of Products detailed in Exhibit D; (c)
requested delivery date; and (d) shipping instructions and shipping address. The Distributor will
submit purchase
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
orders to the Company based on purchase orders the Distributor receives from the
end user customers. Products will be shipped and delivered only after Distributor submits a
purchase order to the Company.
2.2 Acceptance of Orders. All purchase orders are subject to acceptance by the
Company, and no order will be binding upon the Company until the same has been accepted in writing
or by e-mail by the Company. Purchase orders for the Products must be received by the Company at
least **** days prior to the delivery date requested. Each purchase order will be deemed to be an
offer by the Distributor to purchase the Products pursuant to the terms of this Agreement and, when
accepted by the Company, will give rise to a contract between the Distributor and the Company for
the sale of the Products ordered and will be subject to and governed by the terms of this
Agreement. The terms and conditions of this Agreement will govern and supersede any additional or
contrary terms set forth in the Distributor’s purchase order or any Company or the Distributor
acceptance, confirmation, invoice or other document unless duly signed by an officer of the
Distributor and an officer of the Company and expressly stating and identifying which specific
additional or contrary terms will supersede the terms and conditions of this Agreement. It is
expressly understood that the obligation of the Company to sell any Product to the Distributor is
subject to the availability of such Product. The Company reserves the right to allocate available
supplies of the Products among its distributors and customers as it, in its sole discretion,
determines to be appropriate. The Company will make reasonable efforts to fill each order that is
accepted, but the Company will not be liable for damages caused by failure to ship or delay in
shipment resulting from conditions beyond the control of the Company including, but not limited to,
the inability of its suppliers to obtain materials and supplies or to produce sufficient components
to meet Product sales demands.
2.3 Forecasts. Upon execution of this Agreement, the Distributor will provide the
Company with a written twelve (12) month forecast of its expected orders of Products in the
Territory. Thereafter, on the 10th day of each month, the Distributor will furnish to the Company a
written rolling twelve (12) month forecast of its expected orders of Products in the Territory.
Each forecast provided to the Company will constitute a non-binding good faith estimate of expected
orders for Products. Except for the Minimum Product Requirement (defined in Section 5.1 below), the
Distributor will not be obligated to purchase, and the Company will not be obligated to deliver,
any units of Products unless the Distributor has submitted, and the Company has accepted and
consented, a written firm purchase order. In the event the Distributor places a purchase order less
than **** days in advance of the requested delivery date for Products exceeding the applicable
forecast, the Company shall make commercially reasonable efforts to promptly fill such purchase
orders and shall schedule delivery into future periods and communicate such schedule to the
Distributor.
2.4 Shipment. All Products sold to the Distributor by the Company in accordance with
an accepted purchase order will be shipped by the Company to the Distributor ExWorks
(“ExWorks” as defined by Incoterms 2000) at the Company’s loading dock in Xxx Xxxxxx
Xxxxxxx, Xxx, Xxxxxx (the “Shipping Point”). The Distributor assumes all risk of loss
upon the Company’s delivery of the Products to the Distributor’s designated carrier at the Shipping
Point, and the Company will have no further responsibility for the Products. The Distributor agrees
to
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
pay (or reimburse the Company if the Company shall be required to make such payment) all
loading, freight, shipping, insurance, forwarding and handling charges, taxes, fees, storage, and
all other charges applicable to the Products after they are delivered by the Company at the
Shipping Point. Title to all goods will remain in the Company until payment for such goods has been
fully received by the Company. The Company reserves all rights with respect to delivered Products
permitted by law, including without limitation the rights of rescission, repossession, resale, and
stoppage in transit, until the full amount due from the Distributor in respect of all delivered
Products has been paid.
2.5 Modification of Orders. No accepted purchase order will be modified or canceled
except upon the written agreement of both parties. The Distributor’s purchase orders or mutually
agreed change orders will be subject to all provisions of this Agreement, whether or not the
purchase order or change order so states.
2.6 Inspection and Acceptance. The Distributor will conduct any incoming inspection
tests on the Products within ten (10) days of receipt by the Distributor. In the event of any
shortage, damage or discrepancy in or to a shipment of Products, the Distributor, will within ten
(10) days thereafter give notice thereof to the Company and will furnish such written evidence or
other documentation as the Company may deem appropriate. If such evidence indicates, in the
Company’s judgment, that such shortage, damage or discrepancy existed at the time of delivery of
the Products to the carrier, the Company will promptly deliver additional or substitute Products to
the Distributor. In addition, in such event, the Company will pay all loading, freight, shipping,
insurance, forwarding and handling charges, taxes, fees, storage and other charges applicable to
such additional or substitute Products. Any Products not rejected by the Distributor by written
notice given to the Company within such (20) twenty-day period will be deemed to have been accepted
by the Distributor. Following any such acceptance, the sole remedies of the Distributor with
respect to damage to or defects in the Products will be those set forth in Section 8.1.
3. Prices and Payments
3.1 Prices. The transfer price of all Products sold hereunder, ExWorks Shipping Point,
will be the prices set forth on Exhibit C. Price changes will not apply to purchase orders
received and accepted by the Company for delivery prior to the effective date of any price change.
3.2 Payment Terms. The Company will invoice the Distributor upon shipment of
Products. All invoices will be due and payable to the Company through wire transfer, in full within
**** days from the date of the invoice. At any time during the term of this Agreement, the
aggregate amount of all invoices due and payable to the Company will not exceed the amount set
forth in Exhibit C attached hereto (the “Maximum Amount”). In the event any purchase order
issued by the Distributor involves payments to the Company which, together with all other
amounts due to the Company by Distributor will exceed the Maximum Amount, all such exceeding
amounts will be paid to the Company by the Distributor in advance upon the delivery to the Company
of such purchase order. Interest at the rate of **** % per month, or such lesser
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
rate as is the
maximum rate of interest permitted by law, will be charged on all overdue accounts. Notwithstanding
the above, from and after an overdue invoice has not been paid in full within **** days of the ****
days detailed hereinabove, all payments hereunder will be made by irrevocable letter of credit in
form satisfactory to the Company advised through and/or confirmed by a bank designated by the
Company. Such letter of credit must be opened or confirmed by such bank at least **** days prior to
the requested delivery date of the Products covered; must permit partial payment; must provide for
payment to the Company of the purchase price plus prepaid freight, costs and insurance, if any,
upon presentation of shipping documents and the overdue invoice in accordance with the terms of
such letter of credit; and must be payable immediately upon presentation of appropriate shipping
documentation and the overdue invoice. In the event the Distributor fails to meet such terms of
payment, in addition to and not by way of limitation of the Company’s other rights under this
Agreement and at law, the Company reserves the right at any time to alter terms of payment so that
future shipments will be made only on such basis as the Company determines will ensure payment for
such shipments. All payments made under this Agreement will be made in U.S. dollars, free of any
currency control or other restrictions.
3.3 Taxes. The Distributor will be responsible for, and will pay or reimburse the
Company for, all taxes, duties, import deposits, assessments and other governmental charges,
however designated, based on the amounts payable hereunder, or on the Products, their import into
the Territory or their sale or use, which are now or hereafter imposed under or by any governmental
authority or agency. All payments to be made by the Distributor to the Company pursuant to this
Agreement represent net amounts the Company is entitled to receive and will not be subject to any
deductions for any reason whatsoever. In the event any of the payments to be made by the
Distributor to the Company pursuant to this Agreement become subject to taxes, duties, assessments
or fees of whatever kind levied in the Territory, said payments to the Company will be increased to
such an extent as to allow the Company to receive the net amounts due under this Agreement.
3.4 Resale Prices. The Distributor may resell the Products at such prices as it, in
its sole discretion, determines. The Distributor will, provide the Company, in writing on a monthly
basis, with the monthly average selling prices of the Products in the Territory.
4. General Obligations of Distributor.
4.1 Marketing. The Distributor will act in a diligent manner to further the
promotion, marketing, sale and other distribution of the Products in the Territory.
4.2 Responsibilities. Without limiting the generality of Section 4.1, the Distributor
will:
(a) respond to any reasonable requests for market information requested by the Company
and provide the Company written responses to such requests.
(b) maintain an adequate sales force dedicated on a full-time basis necessary for the
sale and support of the Products in the Territory.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
(c) ensure that its sales personnel representing the Products receive complete training
with respect to the promotion and use of the Products, as provided by the Company.
(d) ensure that its sales personnel undertake regular visits to customers or potential
customers in order to establish or maintain, as the case may be, a personal relationship
with such customers and provide support and services for the end user customers of the
Products in accordance with the Company’s services and support policies as amended from time
to time.
(e) participate actively in sales, marketing and servicing programs prepared by the
Company and develop and implement sales programs for the promotion of the Products in a
scope of not less than the scope set forth in Exhibit G.
(f) attend and provide support for the Products at appropriate medical trade shows and
congresses each year in the Territory, as agreed upon by the Company and the Distributor, in
a scope of not less than the scope set forth in Exhibit G; the Distributor shall pay
all related costs.
(g) to the extent requested by the Company, provide personnel and logistical support
for clinical studies of the Products and publication of clinical study results in medical
journals.
(h) support and promote active clinical use of the Products.
(i) maintain an adequate and balanced inventory of the Products and related supplies
and accessories so as to be able to promptly fill all orders from customers; the Distributor
shall allow the Company to review actual inventory levels and suggest target levels of
inventory upon request by the Company. The Distributor will sell such inventory on a FIFO
basis.
(j) provide monthly written inventory counts of the Product(s) to the Company no later
than the 5th day following a calendar month ending date.
(k) ensure at all times proper storage and handling procedures for the Products, taking
all steps to avoid subjecting the Products to excessive heat, sunlight, humidity, dryness,
insects or animals, or other damaging conditions and will comply with all the Company’s
instructions with regard to the same, as provided to the Distributor by the Company from
time to time.
(l) promptly respond to all inquiries from customers, including complaints, process all
orders, and effect all shipments of the Products; the Distributor shall provide the Company
with written summaries of such inquiries and responses on a monthly basis.
(m) shall be responsible as the first point of contact for technical support with the
customer and/or end-users. The Distributor will provide a line of communications
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
directly to
the Company and the Authorized Representative named in Exhibit F in matters of
vigilance and post-market surveillance (early warning) in accordance with any applicable
law, rule or regulation, including the European Commission Guidelines On A Medical Devices
Vigilance System. The Distributor will further provide this technical support on the usage
of Products to the customers based on information supplied by the Company from time to time.
Customer feedback, the occurrence of incidents, near-incidents and inquires from Competent
Authorities (as defined below) will be reported by the Distributor within three (3) business
days directly to the Company contacts named in Exhibit F, or within such earlier
period enabling the Company to properly comply with any reporting obligations under any
applicable law. The Distributor’s reporting should follow the European Commission Guidelines
On A Medical Devices Vigilance System.
(n) establish and maintain a complaint file of any information, including written and
oral communications, received by the Distributor or any subdistributor and agent concerning
customer feedback, the occurrence of incidents and near-incidents and allow the Company, any
Authorized Representative appointed by the Company or any relevant national authority to
inspect and review such complaint file.
(o) establish and maintain traceability to the Product lot number and related supplies
and accessories to the customers; in the matter of vigilance, the Distributor shall provide
the traceability of the particular units requested by the Company within a reasonable time,
not to exceed five (5) days.
(p) diligently investigate and pursue all leads with respect to potential customers
referred to it by the Company and, upon request of the Company, report the status of such
leads and inquiries.
(q) provide the Company contemporaneously with the execution of this Agreement with a
comprehensive marketing plan, developed in conjunction with the Company’s marketing
department, in the form and detail reasonably requested by the Company, and update such
marketing plan with respect to each forthcoming calendar year (divided into 12 monthly
periods) prior to the end of the then-current year or at such intervals as the Company may
otherwise require. The Company hereby acknowledges that the marketing plan provided by the
Distributor upon execution of this Agreement is in a form and detail that is acceptable for
purposes of this Section 4.2(n).
(r) provide the Company within ten (10) days of the end of each quarter a detailed
written report of the Distributor’s sales and marketing activities, of all installed base
(i.e. hospitals or other medical centers in which the Company’s Console Product (as defined
in Exhibit A herein) is installed or based, and of all sales of the Products during
such quarter, including quantity of Products sold by product and model, by end customer,
including address, and the average sale price for each of the Products for such quarter.
(s) transmit promptly to the Company all inquiries and orders received by the
Distributor from customers located outside the Territory.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
(t) provide its customers with all necessary and appropriate training and support
regarding the use of the Products and maintain reasonably detailed records of such training.
(u) within fourteen (14) days of the request by the Company, provide the Company with
quarterly financial statements and any financial information with regard to any limitations,
confines or restrictions on the Distributors bank accounts or banking credit facilities.
(v) permit the Company, any Authorized Representative appointed by the Company and any
relevant national authority, upon reasonable notice, to visit and observe the Distributor’s
places of business and those of the Distributor’s subdistributors and accompany the
Distributor or any subdistributor or agent permitted to be appointed by the Company pursuant
to Section 1.3 during sales calls or training sessions with customers.
(w) not, in any way, alter the Products or remove, cover, change, alter or add to the
labels attached to the Products by the Company, except with the Company’s prior written
approval.
For the avoidance of doubt and unless otherwise explicitly provided herein, the Distributor
will not be entitled to any compensation for the performance of the above obligations.
4.3 Support of Products. The Distributor will provide such after-sales services which
the Company will from time to time specify that the Distributor perform for customers within the
Territory and will at all times maintain a sufficient staff of resident personnel fully trained and
qualified to perform such support services.
4.4 Purchase of Demonstration Products. In consultation with the Company and based on
the limitations detailed herein, the Distributor will deliver a purchase order to the Company for
the receipt of Products for demonstration purposes only. Such Products for demonstration purposes
will not be used for resale and will be comprised of non functional Catheters (as such term is
defined in Exhibit A hereto) at the quantities set forth on Exhibit C (as amended by the
parties upon the inclusion of additional products in this Agreement) and shall be free of charge.
Notwithstanding the above, any delivery of Products for demonstration purposes will be subject to
the availability of such non-functional Products by the Company, taking into account, among others,
the Company’s obligations to provide such non-functional Products to other distributors.
4.5 Product Manager and Training. The Distributor shall maintain a product manager
designated to the Products. The Distributor will, at least three times per year during the term of
this Agreement, send all sales representatives and any other person (including any subdistributors
or agents permitted to be appointed by the Company pursuant to Section 1.3) who will promote,
market, sell or otherwise distribute the Products in the Territory to a place in the
Territory for sales and support services training concerning the Products at Distributor’s
expense. In the event improvements to the Products or additional Company products are added to
this
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
Agreement and included within the definition of “Product” from time to time pursuant to
Section 1.1, the Company will, in its sole discretion, provide similar training. All employees or
other individuals sent by the Distributor to the Company’s headquarters or such other site for
sales and support services training concerning the Products should be able to speak, read and write
English and must have a solid understanding of cardiac medical devices. The Distributor may,
however, send a translator to assist such employees or other individuals sent by the Distributor in
the training process, including assisting such persons in understanding the examinations required
below. The Distributor will be responsible for all travel (including travel to and from Israel),
hotel and subsistence expenses incurred by its employees and other individuals receiving training
hereunder (and the translator). The Company will not be liable for any injury or property damage
suffered by the Distributor’s employees or other individuals receiving training hereunder (or the
translator). The Company will have the right to discontinue training pursuant to this Agreement and
withhold certification without further liability to the Distributor, as to any employee of the
Distributor or other individual who is unable to pass required written, oral and/or practical
examinations by the Company.
4.6 User Manuals and Marketing Materials. The Distributor shall be responsible for the
preparation of sales literature, advertising materials, user documentation, user manuals, sales and
marketing materials for the training, marketing and sale of the Products (collectively,
“Materials”) for use in the Territory, including the translation, adaptation and/or modification of
the Company’s Materials, as deemed appropriate by the Distributor, to reflect the culture or
business practices and languages of the Territory and in accordance with the Company’s policy with
regard to the Materials, in the Company’s sole and absolute discretion. The Distributor will
prepare all Materials in compliance with all applicable laws and shall submit any newly created
Materials to the Company for its prior written approval before using or distributing such
Materials. A final copy of all translated Materials, together with a certification that the
translation accurately reflects the contents of the original English language version, shall be
forwarded to the Company for its records.
4.7 Misrepresentations. The Distributor will not make any false statements,
representations, warranties or advertisements regarding any of the Products which exceeds in scope
or is different in meaning from the statements made by the Company in its own literature or
specifications or approved indications for use or regarding the Company in promoting sales of the
Products, and the Distributor will hold the Company harmless from and indemnify it against any
liability which may arise out of, or result from, any such false representation.
4.8 Records, Recall and Audit. The Distributor will maintain complete and accurate
written records of all Products sold by the Distributor and any subdistributors or agents permitted
by the Company to be appointed pursuant to Section 1.3 and will maintain and provide such other
records and reports as the Company may reasonably request. The Distributor will notify the Company
immediately and confirm such notice in writing if the Distributor obtains information indicating
that any of the Company’s Products may have to be recalled, either by virtue of applicable law or
good business judgment. In the event of a recall of any of the Products, the
Distributor will cooperate fully with the Company in effecting such recall, including without
limitation, immediately contacting any purchasers that the Company desires to be contacted and
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
promptly communicating to such purchasers the information or instructions the Company desires to be
transmitted. The Distributor agrees to comply with any and all traceability programs in effect at
any time as initiated by the Company. The Distributor will permit the Company, any of the Company’s
Authorized Representatives and any relevant national authority to examine, inspect and audit such
records and make transcripts of any records required as part of a traceability program at
reasonable times during business hours. The Company shall have the right to hire an independent
certified public accountant to inspect all such records so required to be kept by the Distributor
(which accountant shall agree in writing to keep all information confidential except as needed to
disclose to the Company any discovered discrepancies); provided, such audit: (i) is conducted
during normal business hours, (ii) is conducted no more often than once per year (unless a
discrepancy is discovered), and (iii) is conducted only after the Company has given the Distributor
five (5) days prior written notice. The Company shall bear the full cost and expense of such audit,
unless a discrepancy is discovered, in which event the Distributor shall bear the full cost and
expense of such audit. Regardless of the amount of discrepancy discovered, all discrepancies (and
interest thereon) shall be immediately due and payable.
4.9 Import Approvals. The Distributor will be responsible for obtaining any required
licenses and permits and for satisfying all formalities as may be required to import the Products
by the Distributor into the Territory in accordance with then prevailing legislation. Each party
will cooperate fully with the other and provide all reasonable assistance to the other in
connection with obtaining any licenses or approvals contemplated by this section.
4.10 Regulatory Compliance and Licenses. The Distributor agrees, at all times during
the term of this Agreement to fully and accurately comply with all applicable laws, regulations,
rules, standards, regulatory regulations and other instructions in the Territory applicable to the
Distributor’s purchase, storage, record keeping, promotion and resale of the Products. The
Distributor will obtain all required licenses, permits, authorizations, filings and registrations
that may be required by any governmental agency or law relating to the sale of the Products in the
Territory (collectively, the “Licenses”) at Distributor’s expense, excluding the CE Xxxx required
for the distribution of the Products in the European Community, or certify to the Company that such
Licenses are not required; all such required Licenses will be in the name of the Company, except
where prohibited by applicable law or regulation. In the event that such Licenses are not permitted
under applicable law to be made in the name of the Company, the Distributor will cause such
Licenses to be issued jointly in the name of the Company and the Distributor. In the event that
such Licenses are not permitted under applicable law to be made in the name of the Company or
jointly in the name of the Company and the Distributor, the Distributor will cause such Licenses to
be issued in the name of the Distributor. In any situation in which any Licenses are not solely in
the name of the Company, the Distributor will and hereby does, to the extent permitted by
applicable law, assign all rights and privileges in connection therewith to the Company or its
designee as soon as is reasonably practicable but no later than sixty (60) days after termination
or expiration of this Agreement. Any documents submitted or filed in order to obtain such Licenses
shall be subject to the Company’s written approval prior to their submission
or filing. Distributor shall provide the Company with full copies of any correspondence and
any other documents exchanged regarding said Licenses within 2 (two) business days of their
receipt.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
Alternatively, the Company may choose, in its sole discretion, to obtain any or all of the
required Licenses and in such event, the Distributor shall cooperate with the Company to obtain
such Licenses.
5. Minimum Product Requirements of Distributor
5.1 Minimum Product Requirements. The Distributor agrees to purchase from the Company,
at least the minimum quantities of Products in accordance with attached Exhibit D (the
“Minimum Product Requirement”), as amended from time to time by mutual written agreement of the
parties hereto. In the event the Distributor does not meet the Minimum Product Requirement for any
quarter it must exceed the Minimum Product Requirement for the quarter immediately following such
quarter by the number it needed to meet the Minimum Product Requirement for the previous quarter.
If Distributor fails to meet the Minimum Product Requirement plus the number it needed to make up
for a previous quarter’s shortfall, the Distributor shall have failed to meet its obligations under
this Section and the Company shall be entitled to terminate this agreement in accordance with the
provisions of Section 5.2 hereunder. Notwithstanding the aforesaid, it is hereby agreed that in the
event a Change of Control (as such term is defined in Section 7.3 below) occurs in the Company
within 6 (six) months following the termination of the Agreement in accordance with the provisions
of Section 5.2 below, the Distributor shall be entitled to the liquidated damages detailed in
Section 7.3 below.
5.2 Special Right to Terminate or Convert Agreement. The Distributor understands and
agrees that the establishment and achievement of the Minimum Product Requirement pursuant to
Section 5.1 is the essence of this Agreement and that any failure by the Distributor to satisfy its
obligations under Section 5.1 will entitle the Company to terminate this Agreement upon ninety (90)
days’ written notice pursuant to Section 7.2, or, alternatively, the Company will be entitled, in
its sole discretion, to convert this Agreement into an entirely non-exclusive distributor
agreement.
6. General Rights and Obligations of the Company
6.1 Marketing and Support. The Company will provide training for the Distributor’s
sales personnel representing the Products with respect to the promotion and use of the Products, in
the scope detailed in Exhibit G and refer to the Distributor for follow-up customer
inquiries and orders received by the Company from prospective customers located in the Territory.
6.2 Sales Materials and User Documentation. The Company will provide the Distributor
with a copy of any Materials developed by the Company for the Products in English. The Distributor
will not use any other sales Materials, except those prepared in accordance with Section 4.6 above.
All expenses incurred by the Distributor with respect to creating sales and Materials and
advertising and promoting the Products will be borne by the Distributor. The Distributor will
provide the Company with a reasonable quantity of Materials prepared by the Distributor.
6.3 Product Changes. The Company reserves the right, in its sole discretion and
without incurring any liability to the Distributor, to:
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
(a) alter the specification for any Product or component thereof;
(b) discontinue the manufacture of any Product or component thereof;
(c) discontinue the development of any improvement to a Product or new product, whether
or not such improvement or product has been announced publicly; or
(d) commence the manufacture and sale of improvements to Products or new products
having features which make any Product wholly or partially obsolete, whether or not the
Distributor is granted any distribution rights in respect of such improvement or new
products pursuant to Section 1.1.
Notwithstanding the above, the Company will use reasonable efforts to provide the Distributor
with prompt written notice of such decisions and will fill all accepted purchase orders from the
Distributor for any such altered or discontinued Products of which manufacturing and commercial
deliveries have commenced.
6.4 Export Approvals. The Company will use reasonable efforts to obtain any required
export licenses and other authorizations and permits from Israel or other applicable governments
for the sale of the Products to the Distributor.
7. Term and Termination
7.1 Term. This Agreement will take effect as of the date first above written and,
unless terminated earlier pursuant to Section 7.2, will continue in force until three (3) years
after the date that the first CE Xxxx approval has been obtained for any of the Products (the “CE
Approval”), at which time this Agreement will automatically expire and terminate unless the parties
mutually agree otherwise in writing. It is hereby agreed that in the
event that during the term of the Agreement the Company does not
obtain **** for its **** until ****, then, the Distributor shall be
entitled to a **** compensation for each month such approval is
delayed, for a maximum period of **** months starting from ****. Payment of such compensation,
if and to the extent paid by the Company, shall be made at the end of
each calendar month after the month for which such compensation is
being made. It is hereby agreed that the compensation detailed herein
shall be the sole and exclusive remedy available for Distributor in
any delay or failure by the Company to obtain the ****.
7.2 Termination. Notwithstanding the provisions of Section 7.1, this Agreement may be
terminated in accordance with any of the following provisions:
(a) The parties may mutually agree in writing to terminate this Agreement at any time
and for any reason.
(b) Either party may terminate this Agreement by giving notice in writing to the other
party should an event of Force Majeure (as defined below) continue for more than six (6)
months.
(c) The Company may terminate this Agreement immediately in the event of any of the
following:
(i) the death, incapacity or discontinuation of an active relationship with the
Distributor for any reason of the individuals named on Exhibit E
attached hereto.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
(ii) “Cause,” which includes, without limitation, (a) fraud, misappropriation
of property, deliberate injury or attempted injury, by the Distributor or any
employees or agents of the Distributor and in each case related to the Company; (b)
any criminal activity by the Distributor or any employees or agents of the
Distributor; (c) the Distributor selling any Products, directly or indirectly, to
customers located outside the Territory; (d) violation by the Distributor of the
covenant not-to-compete set forth in Section 1.4 or its confidentiality undertakings
under this Agreement; (e) payment or non-payment by the Distributor of any invoice
more than thirty (30) days later than the applicable due date of the invoice
pursuant to Section 3.2; or (f) the breach by the Distributor of any other
provision of this Agreement and the failure of the Distributor to cure such breach
within thirty (30) calendar days after receipt of written notice from the Company
requesting such breach to be cured.
(iii) any material change in the general management, ownership, or control of
the Distributor, including any sale, transfer, or relinquishment by the Distributor,
or by an individual named in Exhibit E attached hereto, of any substantial
interest in the ownership of the business carried on by the Distributor under this
Agreement, unless such change is approved in advance and in writing by the Company;
(iv) the Distributor makes an assignment for the benefit of creditors; the
institution of voluntary or involuntary proceedings by or against the Distributor
under bankruptcy or insolvency laws; any general suspension by the Distributor of
payments to creditors; the Distributor files a petition of any type as to its
bankruptcy, is declared bankrupt, becomes insolvent, or goes into liquidation or
receivership; or any similar actions by or against the Distributor in respect of
bankruptcy, insolvency or actions taken by creditors generally.
(d) The Company may terminate this Agreement upon ninety (90) days’ prior written
notice if the Distributor fails to meet the Minimum Product Requirement detailed in Section
5.1; and the Company elects to terminate this Agreement instead of converting this Agreement
into a non-exclusive arrangement pursuant to Section 5.2.
(e) The Company may terminate this Agreement pursuant to Sections 7.3 or 7.4.
(f) The Company may terminate this Agreement in the event that all Licenses have not
been obtained pursuant to Section 4.10 within one year from the date first above written.
7.3 Change of Control of the Company. Notwithstanding the provisions of Section 7.1,
the Company may terminate this Agreement upon ninety (90) days’ written notice in the event of any
material change in the control of the Company, including any sale or transfer of the
business to which this Agreement relates, the sale of all or substantially all of the assets
of the Company, a merger of the Company into another entity in which the Company does not survive
and the acquisition by another person or group of persons acting together of at least fifty percent
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
(50%) of the outstanding voting capital stock of the Company (a “Change of Control”). The Company
and the Distributor agree that it would be impracticable or extremely difficult to fix the actual
damages resulting from a termination of this Agreement by the Company in the event of a Change of
Control of the Company under Section 7.2(e) and this Section 7.3. Therefore, the Company and the
Distributor agree that if the Company terminates this Agreement during the term of this Agreement
pursuant to Section 7.2(e) and this Section 7.3, the Company will pay the Distributor as liquidated
damages, and not as a penalty, an amount equal to the greater of: (a) One hundred twenty five thousand US Dollars ($125,000); or (b) the dollar amount of the
Distributor’s gross profit resulting from the resale by the Distributor of Products purchased under
this Agreement during the previous 6 months prior to the date of termination, or such shorter
period of time during which the Distributor has resold Products purchased under this Agreement; such damages to be payable in 3 equal monthly installments
following the date of termination. The parties agree that the foregoing
liquidated damages represent a reasonable endeavor by the parties to estimate a fair compensation
for the foreseeable losses that might result from such termination of this Agreement by the Company
pursuant to Sections 7.2(e) and this Section 7.3. The Distributor’s sole remedy in the event of
such termination of this Agreement by the Company will be the liquidated damages provided for in
this Section 7.3.
7.4 Termination by the Company; Partial Termination.
(a) In the event the Company terminates this Agreement during the term of this
Agreement for reasons other than those described in Section 7.2, the Company will pay the
Distributor as liquidated damages, and not as a penalty, an amount
equal to the greater of: (a) One hundred twenty five thousand US Dollars ($125,000); or (b) the dollar amount of the
Distributor’s gross profit resulting from the resale by the Distributor of Products purchased under
this Agreement during the previous 6 months prior to the date of termination, or such shorter
period of time during which the Distributor has resold Products purchased under this Agreement; such damages to be payable in 3 equal
monthly installments following the date of termination.
(b) In the event the Company has the right pursuant to the provisions of Section 7.2 to
terminate this Agreement in its entirety, the Company may elect to terminate this Agreement
solely as it applies to any specific Product by providing the Distributor with written
notice in accordance with the relevant Section referred to above; provided, that nothing in
this Section 7.4(b) will be construed as creating a precondition to or otherwise precluding
the Company from terminating this Agreement in its entirety in accordance with the terms of
Section 7.2.
7.5 Rights and Obligations on Termination. In the event of the expiration or
termination of this Agreement for any reason, the parties will have the following rights and
obligations:
(a) Termination of this Agreement will not release either party from the obligation to
make payment of all amounts then or thereafter due and payable.
(b) If and to the extent applicable, the Company will have the right, at its option, to
repurchase from the Distributor all or any part of the Distributor’s inventory of Products
in good repair and which are in good re-sellable condition in the Distributor’s possession,
as of the termination date at the Company’s invoiced price (exclusive of any shipping or
packaging charges or taxes) to the Distributor for such Products. The Company may exercise
its option under this Section 7.5(b) by notifying the Distributor
in writing no later than thirty (30) days after the effective termination date. The Company may deduct any amounts owed to
it by the Distributor, whether for payment of Products or otherwise, from the amount due the
Distributor for the repurchase by the Company of the
Products. The Distributor will be permitted to resell any such inventory of Products
that the Company does not repurchase from the Distributor for a
period of 3 months
following the termination of the Agreement.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
(c) The Distributor’s and The Company’s obligations pursuant to Sections 1.3, 1.4, 4.8,
4.10, 7.5, 7.6, 7.7, 10.3 and Articles 8, 9, 11, 12, 13, 14 and 15 will survive termination
of this Agreement until the obligations set forth in the applicable section are fully
satisfied and the statute of limitations has expired with respect to such obligations.
(d) Within thirty (30) days of the date of termination, the Distributor will furnish to
the Company a list of all the Distributor’s active sales leads, current customers and the
place of destination of all Products sold or distributed in the immediately preceding twelve
(12) months and all Products whose shelf-life has not yet expired.
(e) Upon termination, the Distributor will discontinue the use of any and all
advertising and promotional activities, and will immediately return, at the Company’s
expense, any equipment, product literature, training materials or other items provided by
the Company; provided, however, that with respect to any Products subject to Section 7.5(b)
above, if and to the extent applicable, the Distributor will not be under any obligation to
return such Products unless and until the Company has given the Distributor notice of the
Company’s intention to exercise its option under Section 7.5(b) and has paid for such
Products.
(f) For the avoidance of doubt, after the termination or expiration of this Agreement
for any reason whatsoever, the Company shall be free to directly or indirectly contact and
engage in business with any and all of the Distributor’s customers with respect to the
Product and the Distributor shall not be entitled to any compensation from the Company with
respect to the aforesaid.
7.6 Right to Terminate. It is expressly understood and agreed that the rights of the
Company and the Distributor to terminate this Agreement pursuant to Section 7.2 are absolute, and
that the parties have considered the possibility of such termination and the possibility of loss
and damage resulting therefrom in making expenditures related to the performance of this Agreement.
Except as set forth in Sections 7.3 and 7.4, it is the express intent and agreement of the parties
that neither will be liable to the other for damages or any other compensation by reason of the
termination of this Agreement in accordance with Section 7.1 above.
7.7 Termination of Subdistributors and Agents. Any and all agreements between the
Company and any of the Distributor’s subdistributors and/or agents permitted in accordance with
Section 1.3 above, if and to the extent applicable, will be automatically and immediately
terminated upon the termination of this Agreement for any reason whatsoever, and without any
additional notice or action required to be taken by the Company with regard to such termination.
The Distributor will have sole responsibility for termination of any subdistributor or agent,
including any costs or expenses associated therewith, and will indemnify and hold the Company
harmless from and against any claim, loss, damage or expense (including attorneys’ fees) suffered
or incurred by the Company relating to the termination of any subdistributor or agent
appointed by the Distributor.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
8. Warranty and Liability
8.1 Warranty. The Company warrants to the Distributor that the Products will, when
delivered to the Distributor, be free from defects in materials and workmanship under normal use
and service for a period of **** months from the date of delivery to the Distributor and through
the period of the Company’s published shelf-life for the Products. The Company will in its
reasonable discretion: (a) give the Distributor a full refund of the purchase price of any Product
that it reasonably determines was defective at the time of shipment to the Distributor or that is
the subject of any breach of any warranty by the Company, or (b) replace or repair, in its
reasonable discretion, any Product that it reasonably determines was defective at the time of
shipment to the Distributor or that is the subject of any breach of any warranty by the Company,
provided such Product is returned at the Company’s expense to the Company within the warranty
periods set forth above; provided, however, that the Company will have no obligation under this
warranty to make repairs or replacements necessitated in whole or in part by accidents, fault or
negligence of the Distributor or user. Prior to returning any Product alleged to be defective, the
Distributor will notify the Company in writing of the claimed defect and will include the model and
lot/serial number of such Product, as well as the number and date of the invoice therefor. No
Product may be returned without first obtaining a returned goods authorization from the Company.
8.2 Warranty to Customers. The Distributor will provide each of its customers that
purchases a Product a warranty identical in all material respects to that provided by the Company
to the Distributor pursuant to Section 8.1. The Distributor will provide each of its customers with
documentation provided by the Company, informing each customer that except for a breach of the
specific warranties contained in Section 8.1, the Company shall not be liable for any loss or
damage nor be subject to any other remedy. The Distributor will make no other warranties,
guarantees or representations, whether written or oral, regarding the Products, whether on its own
behalf or on behalf of the Company. Notwithstanding the foregoing, the Distributor will have the
right to translate the warranty into another language; provided, however, that the Company will
have the right to review and approve such translation prior to its distribution to customers. The
Distributor shall include in each of its agreements with its end user customers and/or any
agreement with subdistributors and/ or agents permitted by the Company in accordance with Section
1.3 above, provisions incorporating the terms hereof and confirming the customers’ and/or
subdistributors’ and/or agents’ acknowledgement of and agreement to the same.
8.3 Limited Warranty. THE WARRANTIES SET FORTH IN SECTION 8.1 ARE INTENDED SOLELY FOR
THE BENEFIT OF THE DISTRIBUTOR. ALL CLAIMS HEREUNDER WILL BE MADE BY THE DISTRIBUTOR AND MAY NOT BE
MADE BY THE DISTRIBUTOR’S CUSTOMERS. THE WARRANTIES SET FORTH ABOVE ARE IN LIEU OF ALL OTHER
WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, AND ANY OTHER REPRESENTATIONS, TERMS, OR CONDITIONS,
WHETHER IN CONTRACT, TORT, EQUITY OR OTHERWISE WHICH ARE HEREBY DISCLAIMED AND EXCLUDED BY THE
COMPANY TO THE FULLEST EXTENT PERMISSIBLE BY LAW, INCLUDING
WITHOUT LIMITATION ANY WARRANT FOR MODIFICATIONS TO THE PRODUCTS MADE BY ANYONE OTHER THAN THE
COMPANY (OR ON ITS BEHALF) AND NOT APPROVED BY THE COMPANY IN ADVANCE AND IN WRITING, ANY OTHER ACT
OR OMISSION OF ANYONE OTHER THAN THE COMPANY.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
8.4 Delay. THE COMPANY WILL NOT BE LIABLE FOR ANY LOSS OR DAMAGE CAUSED BY DELAY IN
FURNISHING THE PRODUCTS OR ANY OTHER PERFORMANCE UNDER THIS AGREEMENT.
8.5 Sole Remedies. THE SOLE AND EXCLUSIVE REMEDIES FOR BREACH OF ANY AND ALL
WARRANTIES AND THE SOLE REMEDIES FOR THE COMPANY’S LIABILITY OF ANY KIND (INCLUDING LIABILITY FOR
NEGLIGENCE) WITH RESPECT TO THE PRODUCTS AND ALL OTHER PERFORMANCE BY THE COMPANY UNDER THIS
AGREEMENT WILL BE LIMITED TO THE REMEDIES PROVIDED IN THIS SECTION 8 AND IN SECTION 9.
8.6 Limitation of Liability. THE COMPANY’S LIABILITY TO THE DISTRIBUTOR IN CONNECTION,
DIRECTLY OR INDIRECTLY, WITH THIS AGREEMENT, SHALL NOT EXCEED IN ANY MANNER WHATSOEVER THE AMOUNT
ACTUALLY PAID BY THE DISTRIBUTOR TO THE COMPANY IN THE PRECEDING TWELVE (12) MONTHS.
8.7 Consequential Damages. IN NO EVENT WILL THE COMPANY’S LIABILITY OF ANY KIND
INCLUDE ANY SPECIAL, INDIRECT, PUNITIVE, INCIDENTAL OR CONSEQUENTIAL LOSSES OR DAMAGES, EVEN IF THE
COMPANY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH POTENTIAL LOSS OR DAMAGE.
8.8 Product Liability. Company will have a Product Liability Insurance that covers the
Territory and on which TOP Medical will be named as Distributor for Belgium, The Netherlands and
Luxembourg.
9. Patents and Intellectual Property Rights
9.1 Intellectual Property Rights. Distributor agrees that all the rights with respect
to the Products and Materials, including, without limitation, all apatents, trademarks, copyrights,
services marks, trade names, technology, know how, moral rights and trade secrets, all applications
for any of the foregoing, permits, grants and licenses or other rights relating to the Products and
any improvement, modification, adaptation, innovation, derivation or development made to any of the
Products, including at the request of the Distributor or based on the Distributor’s ideas of
proposals (“Improvements”) (collectively, “Intellectual Property Rights”) are and shall remain at
all times the sole property of the Company. This Agreement shall not, under any circumstance, be
construed to constitute a grant to the Distributor of any Intellectual Property Rights belonging to
the Company, except as expressly provided herein. The Distributor hereby irrevocable assigns (and
shall procure that any subdistributor, if and to the
extent applicable or any employee shall assign) to the Company all right, title and interest
it (or they) have in and to any Improvements and agrees to take all action and to execute all
required documents to affect the same.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
9.2 Defense of Claims. The Company will, at its own expense, defend any suit
instituted against the Distributor which is based on an allegation that any Product constitutes an
infringement third party intellectual property rights. The Company will have control of the
defense of any such action, including any appeals and negotiations for the settlement or compromise
thereof and will have full authority to enter into a binding settlement or compromise. The Company
will indemnify the Distributor against any award of damages and costs made against the Distributor
as a result of any such action.
9.3 Limitation of Liability. The Company will have no liability of any kind to the
Distributor under Section 9.2 or based upon any other claim the Distributor may have to the extent
any such claim is based upon or arises out of (a) the use of any Product in combination with an
apparatus or device not manufactured, supplied or approved in advance and in writing by The
Company, (b) the use of any Product in a manner for which it was not designed or intended to be
used, (c) any modification of any Product by the Distributor or any third party which causes it to
become infringing, or (d) the use of any Product not in full compliance with the Company
instructions enclosed therewith.
9.4 Replacement Product. In order to avoid or limit any liability for infringement,
the Company may, at any time and irrespective of whether it will be obligated to do so by order of
any court, at its own expense and option, replace any Product with a non-infringing item providing
substantially the same performance.
9.5 Infringement. The Distributor will promptly notify the Company as soon as it
becomes aware of any infringement or alleged infringement of any Intellectual Property Rights of
the Company. The Company reserves the right in its sole discretion to institute any proceedings
against such third-party infringers, and the Distributor will refrain from doing so. The
Distributor agrees to cooperate fully with the Company in any action taken by the Company against
such third parties, provided that all expenses of such action will be borne by the Company and all
damages which may be awarded or agreed upon in settlement of such action will accrue to the
Company.
10. Trademarks
10.1 License. The Company hereby grants to the Distributor a non-exclusive,
non-transferable, and royalty-free right and license to use the Company’s trademarks, trade names
and logotypes in connection with the sale, distribution, promotion and advertising of the Products
in the Territory as long as such trademarks are used by the Distributor in accordance with the
Company’s standards, specifications and instructions, but in no event beyond the term of this
Agreement. The Distributor will not acquire any right, title or interest under the laws of any
nation in such trademarks, trade names or logotypes of the Company other than the foregoing limited
license and will not attempt to assert or register any such right, title or interest. The
Distributor will not use any of the Company’s trademarks, trade names or logotypes as part of
the Distributor’s corporate or trade names or permit any third party to do so without the
prior written consent of the Company.
10.2 Infringement. The Distributor will promptly notify the Company of any use by any
third party of the Company’s trademarks, trade names or logotypes or any use by such third
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
parties
of similar marks which may constitute an infringement or passing off of the Company’s trademarks,
trade names or logotypes. The Company reserves the right in its sole discretion to institute any
proceedings against such third-party infringers, and the Distributor will refrain from doing so.
The Distributor agrees to cooperate fully with the Company in any action taken by the Company
against such third parties, provided that all expenses of such action will be borne by the Company
and all damages which may be awarded or agreed upon in settlement of such action will accrue to the
Company.
10.3 Termination of Use. The Distributor acknowledges the Company’s proprietary rights
in and to the Company’s trademarks, trade names and logotypes, and the Distributor hereby waives
all rights to any trademarks, trade names and logotypes now or hereafter originated by The Company.
The Distributor will not adopt, use or register any words, phrases or symbols which are identical
to or confusingly similar to any of the Company’s trademarks. Upon termination of this Agreement,
the Distributor will immediately cease using the Company’s trademarks, trade names and logotypes in
any manner.
11. Confidentiality
Simultaneously with the execution of this Agreement, the parties shall enter into a Non
Disclosure Agreement in the form attached hereto as Exhibit H.
12. Representations, Warranties and Indemnities
12.1 Mutual Representations and Warranties. Each of the parties represents and
warrants to the other that (a) it has the right, power and authority to enter into this Agreement
and perform its obligations hereunder, and has taken all requisite organizational action to approve
and authorize its execution and delivery hereof, (b) this Agreement is valid and binding on it and
enforceable against it in accordance with the terms hereof, and (c) neither the execution nor the
performance of this Agreement will constitute a breach or violation of the terms of its charter,
incorporation or organizational documents or any contract, agreement or other commitment to which
it is a party or by which it or any of its properties are bound.
12.2 Distributor Representation and Warranties. In addition to the aforesaid, the Distributor
represents and warrants to the Company that it has the required knowledge, experience, expertise
and financial capacity to fulfill its obligations hereunder, that it has previous experience and
knowldge regarding products similar to the Products and the applicable market in the Territory,
that it has gathered for itself and received and reviewed all the information deemed required by it
and that it is entering into this Agreement based on its independent analysis and after evaluation
for itself the merits hereof.
12.3 Indemnification by The Company. Subject to Sections 8.3, 8.4 8.5 and 8.6 above,
the Company agrees to indemnify, defend and hold harmless the Distributor and its
subsidiaries, directors, shareholders, officers and employees from and against any amounts paid to
third parties for claims, liabilities, damages, losses, costs and expenses (including reasonable
attorneys’ fees) of any nature (“Indemnifiable Losses”) resulting from or arising out of (a) any
breach of any representation, warranty, covenant or agreement on the part of the Company under
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
this
Agreement, (b) the negligence, intentional or criminal act of the Company, its directors, officers,
employees and agents, or (c) personal injury, product liability or warranty claims of third parties
related to any of the Products, provided however, that the Distributor shall immediately notify the
Company in writing as soon as it becomes aware of such claim and allow the Company to defend such
claim; provided, further, that in no event will the Company be liable for the damages referenced in
Section 8.7 or matters for which the Distributor is responsible under Section 12.4 below.
12.4 Indemnification by the Distributor. The Distributor agrees to indemnify, defend
and hold harmless the Company and its subsidiaries, directors, officers and employees from and
against any amounts paid to third parties for Indemnifiable Losses resulting from or arising out of
(a) any breach of any representation, warranty, covenant or agreement on the part of the
Distributor under this Agreement, (b) the negligence, intentional or criminal act of the
Distributor, its directors, officers, employees and agents, (c) product claims, whether written or
oral, made or alleged to be made, by the Distributor in its advertising, publicity, promotion, or
sale of any Products where such product claims were not agreed to by the Company, or (d) negligent
handling by the Distributor of the Products or changes, additions or modifications to the Products
by the Distributor; provided, however, that in no event will the Distributor be liable for matters
for which the Company is responsible under Section 12.3 above.
13. Jurisdiction
13.1 Disputes. Any dispute, controversy or claim arising out of or relating to this
Agreement, or the breach, termination or invalidity thereof, which is not resolved between the
parties themselves, will be submitted to the competent courts of Tel Aviv, Israel.
13.2 Governing Law. This Agreement will be governed by, and interpreted and construed
in accordance with, the laws of the State of Israel.
14. Force Majeure
14.1 Definition. Force Majeure will mean any event or condition, not existing as of
the date of this Agreement, not reasonably foreseeable as of such date and not reasonably within
the control of either party, which prevents in whole or in material part the performance by one of
the parties of its obligations hereunder or which renders the performance of such obligations so
difficult or costly as to make such performance commercially unreasonable. Without limiting the
foregoing, the following will constitute events or conditions of Force Majeure: riots, civil or
military disturbances, war, strikes, lockouts, labor slowdowns or stoppages, prolonged shortage of
energy supplies, epidemics, fire, flood, hurricane, typhoon, earthquake, lightning and explosion.
It is agreed that any event or condition caused by the unstable political situation in Israel can
not be used as reason for the termination of this Agreement.
14.2 Notice. If a Force Majeure event occurs, a party affected by an event of Force
Majeure will promptly notify the other party of such event. Such notice will include a description
of the nature of the event of Force Majeure, its cause and possible consequences.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
14.3 Suspension of Performance. During the period that the performance by one of the
parties of its obligations under this Agreement has been suspended by reason of an event of Force
Majeure, the other party may likewise suspend the performance of all or part of its obligations
hereunder, except for the obligation to pay any amounts due and owing hereunder, to the extent that
such suspension is commercially reasonable.
15. Miscellaneous
15.1 Relationship. This Agreement does not make either party the employee, agent or
legal representative of the other for any purpose whatsoever. Neither party is granted any right or
authority to assume or to create any obligation or responsibility, express or implied, on behalf of
or in the name of the other party. In fulfilling its obligations pursuant to this Agreement each
party will be acting as an independent contractor. This Agreement will not be construed in any way
to deem the Distributor an agent or franchisee of the Company for any purpose whatsoever. The
parties acknowledge that their relationship under this Agreement is that of supplier and
distributor and not that of principal and agent or of franchisor and franchisee. The Distributor
acknowledges that it has paid no fee or other consideration for any right under this Agreement. It
is the express intent of the parties, pursuant to their right to freedom of contract, that this
Agreement will govern the obligations of each to the other and the right of each resulting from
such relationship and that no state or foreign franchise law or any other law purporting to alter
the relationship between the Company and the Distributor, presently in force or hereafter enacted,
may apply to the rights and obligations of and between the parties under this Agreement. The rights
and obligations of the parties in the event of termination of this Agreement have been separately
bargained for and are intended by both parties to be in lieu of any rights or obligations arising
under any state or foreign franchise law, or any other law purporting to alter the relationship
between the parties. The time within which the Distributor may bring an action for breach of this
Agreement will be one hundred eighty (180) days from the date of such breach. No action may be
commenced after that one hundred eighty (180) day period.
15.2 Assignment. Neither party may assign or otherwise transfer its rights and
obligations under this Agreement without the prior written consent of the other party, except that
the Company may assign this Agreement to any successor in interest of all or substantially all of
the business of the Company, whether by merger, acquisition, operation of law, assignment, purchase
or otherwise, or to any of its subsidiaries and/or affiliates. Any prohibited assignment will be
null and void. All terms and conditions of this Agreement will be binding on and inure to the
benefit of the successors and permitted assigns of the parties.
15.3 Publicity. This Agreement is confidential and no party will issue press releases
or engage in other types of publicity of any nature dealing with the commercial and legal details
of this Agreement without the other party’s prior written approval, which approval will not be
unreasonably withheld. However, approval of such disclosure will be deemed to be given to the
extent such disclosure is required to comply with governmental rules, regulations or other
governmental requirements, including without limitation, any reporting obligations by any
governmental securities authority.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
15.4 Notices. Notice permitted or required to be given under this Agreement will be
deemed sufficient if given in writing by facsimile, commercial air delivery service or by
registered or certified air mail, postage prepaid, return receipt requested, addressed to the
respective addresses of the parties set forth below or at such other address as the respective
parties may designate by like notice from time to time. Notices so given will be effective upon the
earlier of: (a) receipt by the party to which notice is given (which, in the instance of a
facsimile, will be deemed to have occurred at the time that the machine transmitting the facsimile
verifies a successful transmission of the facsimile); (b) on the seventh business day following the
date such notice was deposited in the mail; or (c) on the third business day such notice was
delivered to a commercial air delivery service. Notices will be given as follows:
If to the Distributor:
|
TOP Medical X.X. | |
Xxxxxxxxxxxxx 00 | ||
0000 XX Xxxx | ||
Xxx Xxxxxxxxxxx | ||
Attn: Managing Director | ||
Fax: x00 00 0000000 | ||
If to the Company:
|
TopSpin Medical (Israel) Ltd. | |
0 Xxxxxx Xxxxxx | ||
Xxx 00000 | ||
Xxxxxx | ||
Attn: Chief Executive Officer | ||
Fax: x000-0-0000000 |
15.5 Entire Agreement. This Agreement, including the exhibits attached hereto and
incorporated as an integral part of this Agreement, constitutes the entire agreement of the parties
with respect to the subject matter hereof, and supersedes all previous proposals, oral or written,
and all negotiations, conversations or discussions heretofore had between the parties related to
this agreement. The Distributor acknowledges that it has not been induced to enter into this
Agreement by any representations or statements, oral or written, not expressly contained herein.
15.6 Amendment. This Agreement will not be deemed or construed to be modified,
amended, rescinded, canceled or waived, in whole or in part, other than by written amendment signed
by the parties hereto, except as expressly provided in this Agreement.
15.7 Severability. In the event that any of the terms of this Agreement are in
conflict with any rule of law or statutory provision or otherwise unenforceable under the laws or
regulations of any government or subdivision thereof, such terms will be deemed stricken from this
Agreement, but such invalidity or unenforceability will not invalidate any of the other terms of
this Agreement and this Agreement will continue in force, unless the invalidity or
unenforceability of any such provisions of this Agreement substantially violates, comprises an
integral part of or is otherwise inseparable from the remainder of this Agreement.
15.8 Counterparts. This Agreement will be executed in two or more counterparts in the
English language, and each such counterpart will be deemed an original hereof. In case of any
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
conflict between the English version and any translated version of this Agreement, the English
version will govern.
15.9 Waiver. No failure by either party to take any action or assert any right
hereunder will be deemed to be a waiver of such right in the event of the continuation or
repetition of the circumstances giving rise to such right.
15.10 No Third Party Beneficiaries. This Agreement shall be binding upon and, except
as specifically provided herein, shall inure solely to the benefit of the parties hereto and their
respective successors and assigns.
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
The parties hereto have caused this Agreement to be duly executed by their authorized
representatives as of the day and year first above written.
TOPSPIN MEDICAL (ISRAEL) LTD. | TOP MEDICAL B. V. | |||||||
By:
|
/s/ Xxxx Xxxxx /s/ Xxxx Xxxxx | By: | /s/ Jan-Xxxxxx Xxxxxxxx | |||||
Name:
|
Xxxx Xxxxx & Xxxx Xxxxx | Name: | Jan-Xxxxxx Xxxxxxxx | |||||
Title:
|
CEO & CFO | Title: | Managing Director | |||||
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT A
Product:
Intravascular Catheter for the Coronary Arteries (“Catheter”)
Intravascular MRI Console (“Console”)
Field:
Intravascular MRI Catheter for the Coronary Arteries
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT B
TERRITORY
The Territory:
Benelux (Belgium, The Netherlands and Luxembourg)
2
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT C
CONSIDERATION, PAYMENT SCHEDULE AND INVOICING
Transfer Price per Product:
Catheter: ****
Console: ****
Maximum
Amount (for the Purpose of Section 3.2): ****
Quantities of Demonstration Products: ****
* All Prices quoted herein are net of the taxes detailed in Section 3.3.
3
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT D
MINIMUM PURCHASE REQUIREMENTS
Minimum Purchase Requirements:
Year |
Quarter | Minimum Purchase Requirements* | ||
First Year of the Term
|
Q1 | **** | ||
First Year of the Term
|
Q2* | **** | ||
First Year of the Term
|
Q3 | **** | ||
First Year of the Term
|
Q4 | **** | ||
Second Year of the Term
|
Q1 | **** | ||
Second Year of the Term
|
Q2 | **** | ||
Second Year of the Term
|
Q3 | **** | ||
Second Year of the Term
|
Q4 | **** | ||
Third Year of the Term
|
Q1 | **** | ||
Third Year of the Term
|
Q2 | **** | ||
Third Year of the Term
|
Q3 | **** | ||
Third Year of the Term
|
Q4 | **** |
Minimum Purchase Requirements per each Purchase Order: 1
* | All Minimum Purchase Requirements stated herein are in aggregate amounts in US$. | |
** | Assuming **** is received within **** months from the ****. If the **** shall not be obtained in the aforcmentioned period, then, the requirements detailed herein shall not apply to such period and the Minimum Purchase Requirements detailed in this Exhibit shall be adjusted according to the date in which the **** is obtained. |
4
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT E
KEY INDIVIDUALS
****
5
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT F
The Company’s Regulatory Affairs Contact Details:
TopSpin Medical (Israel) Ltd.
Attn: Regulatory Affairs
0 Xxxxxx Xxxxxx
Xxx 00000
Xxxxxx
Tel: x000-0-0000000
Fax: x000-0-0000000
Email: xxxxxx@xxxxxxx.xx.xx
Attn: Regulatory Affairs
0 Xxxxxx Xxxxxx
Xxx 00000
Xxxxxx
Tel: x000-0-0000000
Fax: x000-0-0000000
Email: xxxxxx@xxxxxxx.xx.xx
Authorized Representative Contact Details:
CEpartner4U BV
Xxxxxxxxxxx 00
0000 XX Xxxxx
Xxx Xxxxxxxxxxx
Tel: x00-0-000-000-00
Fax: x00-000-000-000
Email: xxxxxxxxx@xxxxxxxxx0x.xx
Xxxxxxxxxxx 00
0000 XX Xxxxx
Xxx Xxxxxxxxxxx
Tel: x00-0-000-000-00
Fax: x00-000-000-000
Email: xxxxxxxxx@xxxxxxxxx0x.xx
6
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT G
PROMOTION, MARKETING AND SERVICING SCHEDULE
List of promotion, marketing and servicing tasks of the Distributor under the agreement:
• | Participating in the major interventional cardiology conferences: Euro-PCR, ESC and TCT. Being present in Company booth if applicable, joining meetings and inviting potential customers to the booth. | |
• | Assistance in reviewing and preparing marketing materials, including brochures and presentations. | |
• | Assistance in defining marketing strategy, product positioning and key messages (product strengths, obtaining testimonials from users). | |
• | Assisting the company in arranging visits to key sites. | |
• | Joining meetings with physicians when needed: advisory board meetings, investigator meetings, etc. | |
• | Recommending to the company which regional meetings can be relevant and participating in them with company representatives. | |
• | Assisting company in obtaining co-funding for Post-Marketing Studies from industry partners (device/pharma) on regional level. | |
• | Be trained on the clinical need, the technology and system operation. | |
• | Assist in assembling training program for site initiations (physicians and operators). | |
• | After an agreed number of initiations, take over site initiation and user training programs. | |
• | Be trained on servicing. | |
• | Provide service activity by remote trouble shooting level (phone, email) and provide field service activity (labor) at component level. | |
• | Maintain and manage spare parts per agreed level based on Topspin recommendation | |
7
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
EXHIBIT H
NON-DISCLOSURE AGREEMENT
8
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
NON DISCLOSURE AGREEMENT
This non disclosure agreement (the “Agreement”) is entered into as of the 3rd day
of October, 2006, by and among TopSpin Medical (Israel) Ltd., a company incorporated under the laws
of the State of Israel (the “Company”) whose address for purposes hereof is 2 Yodfat St., Lod (the
“Company”), and Top Medical B.V., a company incorporated under the laws of the state of The
Netherlands (the “Distributor”) whose address for purposes hereof is Xxxxxxxxxxxxx 00, 0000 XX
Xxxx, Xxx Xxxxxxxxxxx.
The Distributor and the Company have executed an Exclusive Distribution Agreement (the
“Distribution Agreement”), and in connection with the same the Distributor has been, and/or will
be, provided with, and/or has access to certain confidential information of the Company. With
respect to any and all information disclosed by the Company to the Distributor, the parties wish to
ensure due protection of such information.
Therefore, the parties hereby agree as follows:
9
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
1. Distributor acknowledges and agrees that it may have access to confidential and proprietary
information concerning the activities and business of the Company, its parent companies,
subsidiaries and/or affiliates, all whether in oral, written, graphic, or machine-readable form, or
in any other form, including, without limitation, concepts, techniques, processes, methods,
systems, designs, drawings, photographs, models, prototypes, computer programs, research materials,
formulas, development or experimental work, work in progress, mask work, inventions, cost data,
marketing plans, product plans, business strategies, financial information, forecasts, personnel
information and customer or supplier lists. Such information, whether documentary, written, oral or
computer generated, shall be deemed to be and referred to as “Proprietary Information”.
2. Notwithstanding the aforesaid, information shall not be deemed as Proprietary Information, for
purposes of this Agreement, if the Distributor can show documentary evidence that: (a) such
information is in the public domain at the time of disclosure, or subsequently becomes part of the
public domain, through no breach of the Distributor of its obligations hereunder; or (b) such
information is received by the Distributor from a third party exempt from confidentiality
undertakings; or (c) such information was in its possession at the time of disclosure, and the
Distributor so advised the Company immediately upon disclosure; or (d) the Distributor is compelled
by court or government action pursuant to applicable law to disclose such information, provided,
however, that the Distributor gives the Company prompt notice thereof so that the Company may seek
a protective order or other appropriate remedy, and further provided that in the event that such
protective order or other remedy is not obtained, the Distributor shall furnish only that portion
of the Proprietary Information which is legally required, and shall exercise all efforts required
to obtain confidential treatment for such information.
3. The Proprietary Information shall be used by the Distributor for the limited purposes set forth
in the Distribution Agreement.
4. The Distributor hereby acknowledges that the Proprietary Information is highly confidential, and
undertakes that, at all times, it: (i) shall treat and maintain the Proprietary Information as
confidential, and hold all such Proprietary Information in trust and in strict confidence,
utilizing the same degree of care it uses to protect its own confidential information, but in no
event less than a reasonable degree of care; (ii) shall not disclose the Proprietary Information to
any third party, whether or not for consideration; (iii) shall not use the Proprietary Information
for any purpose other than the limited purpose mentioned in Section 3 above, or exploit the
Proprietary Information for its own benefit or for the benefit of anyone else, without the prior
written consent of the Company; and (iv) shall not make any copies of the Proprietary Information
without the prior written consent of the Company.
5. Distributor undertakes to hold all Proprietary Information locked and to disclose the
Proprietary Information only to those of its employees and consultants (provided, with respect to
such consultants, that disclosure to any consultant shall be made only after receipt of written
consent of the Company) (each, a “Representative”) who have to be so informed in order to provide
the services pursuant to the Distribution Agreement, and provided that such Representatives are
bound by written confidentiality and non-use undertakings towards
10
PORTIONS OF THIS EXHIBIT IDENTIFIED BY “****” HAVE BEEN DELETED PURSUANT TO A REQUEST FOR
CONFIDENTIAL TREATMENT FILED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER SECTION 406 TO
REGULATION C OF THE SECURITIES ACT OF 1933, AS AMENDED.
Distributor which also apply to the Proprietary Information disclosed to Distributor under this
Agreement. Distributor will be responsible for ensuring that the obligations of confidentiality and
non-use contained herein are observed by all Representatives, and it represents that it has
instituted policies and procedures which provide such adequate protection for the Proprietary
Information. Without derogating from the aforesaid, Distributor shall bear full responsibility for
any harm caused to the Company by disclosure to Representatives.
6. Upon the Company’s first demand, Distributor shall return to the Company all Proprietary
Information, including all records, products and samples received, and any copies thereof, as well
as any notes, memoranda or other writings or documentation which contain or pertain to the
Proprietary Information or any portion thereof, whether in its possession or under its control, and
shall erase all electronic records thereof, an shall so confirm to the Company in writing.
7. Distributor recognizes, acknowledges and agrees that the Company may be irreparably harmed if
the Distributor’s obligations and undertakings herein are not specifically enforced and that the
Company would not have an adequate remedy at law in the event of actual or threatened violation by
the Distributor of such obligations and undertakings. Therefore, the Distributor agrees that the
Company shall be entitled to seek and obtain an injunction, without bond, or to an appropriate
decree of specific performance or any other appropriate equitable relief.
8. The Distributor recognizes that Company will receive confidential or Proprietary Information
from third parties subject to a duty on Company’s part to maintain the confidentiality of such
information and to use it only for certain limited purposes. At all times, both during the term of
this Agreement and after its termination, the Distributor undertakes to keep all such information
in strict confidence and trust, and not to use or disclose any of such information without the
prior written consent of Company, except as may be necessary to perform his duties under the
Distribution Agreement and consistent with Company’s agreement with such third party. Upon
termination of the Distribution Agreement, the Distributor shall act with respect to such
information as set forth in Section 6, mutatis mutandis.
9. The Distributor agrees and declares that all Proprietary Information, patents and other rights
in connection therewith shall be the sole property of Company and its assigns.
10. All of the Company’s rights hereunder and all of the Distributor’s obligations and undertakings
hereunder shall be in full effect for the entire term of this Agreement, and for an unlimited
period of time after its termination, cancellation or expiration for any reason whatsoever.
11. The provisions of Section 15 of the Distribution Agreement shall apply to this Agreement,
mutatis mutandis.
/s/ Xxxx Xxxxx /s/ Xxxx Xxxxx | /s/ Jan-Xxxxxx Xxxxxxxx | |||||||
TopSpin Medical (Israel) Ltd. | TOP Medical B.V. | |||||||
By:
|
Xxxx Xxxxx & Xxxx Xxxxx | By: Jan-Xxxxxx Xxxxxxxx | ||||||
Title:
|
CEO & CFO | Title: Managing Director | ||||||
11